[RTOG 0933] A PHASE II TRIAL OF HIPPOCAMPAL AVOIDANCE DURING WHOLE BRAIN RADIOTHERAPY FOR BRAIN METASTASES

Approval Date:
Principal Investigator:
Eligibility:

Approval Date: 4/25/2012

Principal Investigator: Peter Chen, MD

RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. PURPOSE: This phase II trial is studying how well avoiding the hippocampus during whole-brain radiation therapy works in treating patients with brain metastases.

Eligibility:

Each study has its own guidelines to determine who can participate, called "eligibility criteria", with only the study doctor able to assess whether you meet all of the eligibility criteria. More information can be found at http://clinicaltrials.gov/ct2/show/NCT01227954.

Contact Person:
Kandice Kenney-Cosbitt, RN, Res Coord
248-551-0439

Status of Clinical Trial:
open and enrolling

Contact Person:
Status of Clinical Trial:

Copyright © 2013 Beaumont Health System. All Rights Reserved. Privacy Policy | Site Map